New patient trials surrounding the medication Retatrutide , specifically the 120 milligram formulation ZPHC ZPHC, suggest a impressive impact on physique reduction and associated chronic factors. Experts posit that this dual acting , affecting both GLP-1 and GIP receptors , could provide a substantial advance in the treatment of obesity and relate